WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV

WINTON GROUP Ltd lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 161.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 543,333 shares of the company’s stock after buying an additional 335,269 shares during the quarter. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $8,221,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Bessemer Group Inc. grew its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Xponance Inc. raised its stake in Roivant Sciences by 1.9% in the 3rd quarter. Xponance Inc. now owns 46,718 shares of the company’s stock worth $707,000 after purchasing an additional 882 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in Roivant Sciences by 1.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 86,652 shares of the company’s stock valued at $1,311,000 after purchasing an additional 1,019 shares during the period. Jones Financial Companies Lllp boosted its holdings in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Finally, M&T Bank Corp grew its position in shares of Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Down 3.2%

NASDAQ ROIV opened at $28.78 on Monday. The firm has a market capitalization of $20.60 billion, a price-to-earnings ratio of -24.60 and a beta of 1.17. The firm’s 50 day simple moving average is $24.56 and its 200 day simple moving average is $20.15. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $30.03.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Weiss Ratings cut shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Leerink Partners increased their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Citigroup raised their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $28.81.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the completion of the sale, the chief executive officer directly owned 1,654,597 shares in the company, valued at $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Allen Gold sold 375,784 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $26.50, for a total value of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. This represents a 2.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 13,318,014 shares of company stock valued at $315,727,023 over the last ninety days. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.